<DOC>
	<DOCNO>NCT01376804</DOCNO>
	<brief_summary>This open-label , single arm study evaluate tolerability efficacy Valcyte ( valganciclovir ) prevention cytomegalovirus disease pediatric renal transplant recipient . After transplantation , patient ( age 4 month 16 year ) receive Valcyte orally daily 200 day post-transplant follow 52 week post-transplantation .</brief_summary>
	<brief_title>A Study Oral Valcyte ( Valganciclovir ) Pediatric Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Children , 4 month 16 year age Patient receive kidney transplant At risk develop cytomegalovirus disease Adequate hematological renal function Able tolerate oral medication Negative pregnancy test female childbearing potential Allergic significant adverse reaction acyclovir , valacyclovir ganciclovir past Severe uncontrolled diarrhea ( 5 watery stool per day ) Liver enzyme elevation five time upper limit normal aspartate aminotransferase [ AST ( SGOT ) ] alanine aminotransferase [ ALT ( SGPT ) ] Patient require use protocol prohibit concomitant medication Previous participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>